Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 2, 2006, Pages 159-166

  Robaeys, Geert ^a   Van Vlierberghe, Hans ^b   Matheï, Catharina ^c   Van Ranst, Marc ^d   Bruckers, Liesbeth ^e   Buntinx, Frank ^c  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e HASSELT UNIVERSITY   (Belgium)

Author keywords

Cohort study; Hepatitis C; Intravenous; Patient compliance; Substance abuse; Treatment outcome

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; INTERFERON; METHADONE; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; MALE; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33144489685     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200602000-00008     Document Type: Article

References (34)

1. Denis B, Dedobbeleer M, Collet T, Petit J, Jamoulle M, Hayani A, et al. High prevalence of hepatitis C virus infection in Belgian intravenous drug users and potential role of the 'cotton-filter' in transmission: the GEMT Study. Acta Gastroenterol Belg 2000; 63:147-153.
2. Matheï C, Buntinx F, Van Damme R Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J Viral Hepatol 2002; 9:157-173.
3. Bassily S, Hyams KC, Fouad RA, Samaan MD, Hibbs RG. A high risk of hepatitis C infection among Egyptian blood donors: the role of parenteral drug abuse. Am J Trop Med Hyg 1995; 52:503-505.
4. Bolumar F, Hernandez-Aguado I, Ferrer L, Ruiz I, Avino MJ, Rebagliato M. Prevalence of antibodies to hepatitis C in a population of intravenous drug users in Valencia, Spain, 1990-1992. Int J Epidemiol 1996; 25:204-209.
5. Freeman AJ, Zekry A, Whybin LR, Harvey CE, van Beek IA, de Kantzow SL. Hepatitis C prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s. Med J Aust 2000; 172:588-591.
6. Lamden KH, Kennedy N, Beeching NJ, Lowe D, Morrison CL, Mallinson H, et al. Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England. J Infect 1998; 37:260-269.
7. Lorvick J, Kral AH, Seal K, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001; 91:46-47.
8. Novick DM, Reagan KJ, Scott Croxson T, Gelb AM, Stenger RJ, Kreek MJ. Hepatitis C virus serology in parenteral drug users with chronic liver disease. Addiction 1997; 92:167-171.
9. Schreier E, Hohne M, Kunkel U, Berg T, Hopf U. Hepatitis GBV-C sequences in patients infected with HCV contaminated anti-D immunoglobulin and among i.v. drug users in Germany. J Hepatol 1996; 25:385-389.
10. Van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ 1998; 317:433-437.
11. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
12. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778-789.
13. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
14. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
15. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a (40 kilodaltons) and ribovirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
16. Jowett SL, Agarwal K, Smith BC, Craig W, Hewett M, Bassendine DR, et al. Managing chronic hepatitis C acquired through intravenous drug use. Q J Med 2001; 94:153-158.
17. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-193.
18. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002; 36:3210-3219.
19. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67:117-123.
20. Cournot M, Gilbert A, Castel F, Druart F, Imani K, Lauwers-Cances V, et al. Management of hepatitis C in active drug users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004; 28:533-539.
21. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120-124.
22. Neri S, Bruno CM, Abate G, Ierna D, Mauceri B, Cilio D, et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-2b. Clin Ther 2002; 24:1627-1635.
23. Van Vlierberghe H, Leroux-Roels G, Bourgeois N, Adler M, Nevens F, Horsmans Y, et al. Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. J Viral Hepatitis 2003; 10:460-466.
24. Broers B, Giner F, Dumont P, Mino A. Inpatient opiate detoxicification in Geneva: follow-up at 1 and 6 months. Drug Alcohol Depend 2000; 58: 85-92.
25. NIH Consensus Statement, Management of hepatitis C. Vol. 15, no. 3. Bethesda, MD: National Institutes of Health; 1997.
26. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morb Mortal Wkly Rep 1998; 47:1-39.
27. EASL International consensus conference on hepatitis C: Paris, 26-27 February 1999: consensus statement. J Hepatol 1999; 31 (suppl 1):3-8.
28. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345:211-214.
29. Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on inteferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001; 96:157-164.
30. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001; 345:215-217.
31. National Institutes of Health consensus development conference: management of hepatitis C: 2002. Hepatology 2002; 36:S1-S252.
32. Dalgard O, Bjoro K, Helium K, Myrvang B, Skaug K, Gutigard B, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Euro Addict Res 2002; 8:45-49.
33. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin R, Martin G, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443-451.
34. van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroentol 2003; 98:2281-2288.